Gilead Sciences Inc.

GILD-Q

NASDAQ:GILD

69.00
1.88 (2.65%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia

Analysis and Opinions about GILD-Q

Signal
Opinion
Expert
COMMENT
COMMENT
September 22, 2017

This is among biotech stocks which historically, have done very well from April right through until the end of September. It happened again this year, although it didn’t happen last year. Look for an opportunity to take profits on strength.

Show full opinionHide full opinion
Gilead Sciences Inc. (GILD-Q)
September 22, 2017

This is among biotech stocks which historically, have done very well from April right through until the end of September. It happened again this year, although it didn’t happen last year. Look for an opportunity to take profits on strength.

PAST TOP PICK
PAST TOP PICK
September 22, 2017

(A Top Pick Oct 27/16. Up 13%.) Felt that a lot of the pharmaceutical companies had been beaten up and there would be a big uptick. The stock actually went down for quite a while. They did very, very well because of their HIV and hepatitis C drug. The problem with the hepatitis C drug is that they were curing people too quickly. Just made a recent acquisition on the cancer side which pushed the stock up a great deal. He still likes this.

Show full opinionHide full opinion
Gilead Sciences Inc. (GILD-Q)
September 22, 2017

(A Top Pick Oct 27/16. Up 13%.) Felt that a lot of the pharmaceutical companies had been beaten up and there would be a big uptick. The stock actually went down for quite a while. They did very, very well because of their HIV and hepatitis C drug. The problem with the hepatitis C drug is that they were curing people too quickly. Just made a recent acquisition on the cancer side which pushed the stock up a great deal. He still likes this.

HOLD
HOLD
September 14, 2017

They recently made an acquisition. If Kyte was so great why did they sell out? GILD has the ability to take them to market. The knock on the stock has been this cash cow and not reinvesting in their pipeline. They are not into oncology. Novartis got approval on a similar drug recently and that drove the stock higher. You are okay to hold this here. Let’s get through this November date.

Show full opinionHide full opinion
Gilead Sciences Inc. (GILD-Q)
September 14, 2017

They recently made an acquisition. If Kyte was so great why did they sell out? GILD has the ability to take them to market. The knock on the stock has been this cash cow and not reinvesting in their pipeline. They are not into oncology. Novartis got approval on a similar drug recently and that drove the stock higher. You are okay to hold this here. Let’s get through this November date.

COMMENT
COMMENT
September 12, 2017

About 50% of its franchises are based in hepatitis C. You really have to be careful, because this franchise is slowing. They have 2 prospective years of negative earnings growth, which is a huge headwind. Value this on its long-term cash flows. There are 2 things to consider. 1.) How sustainable are they. If that continues, then you have a leg to stand on. 2.) If you have falling rates, that is good for valuation. The problem is, we are probably going to have flat to rising rates, and Pharma M&A is a bit of a dice roll. He doesn’t buy into the story, and would prefer the Spdr S&P Biotech ETF (XBI-N). You could be a little more conservative using the iShares D J Medical Devices ETF (IHI-N).

Show full opinionHide full opinion
Gilead Sciences Inc. (GILD-Q)
September 12, 2017

About 50% of its franchises are based in hepatitis C. You really have to be careful, because this franchise is slowing. They have 2 prospective years of negative earnings growth, which is a huge headwind. Value this on its long-term cash flows. There are 2 things to consider. 1.) How sustainable are they. If that continues, then you have a leg to stand on. 2.) If you have falling rates, that is good for valuation. The problem is, we are probably going to have flat to rising rates, and Pharma M&A is a bit of a dice roll. He doesn’t buy into the story, and would prefer the Spdr S&P Biotech ETF (XBI-N). You could be a little more conservative using the iShares D J Medical Devices ETF (IHI-N).

DON'T BUY
DON'T BUY
September 11, 2017

They made a lot of money on their HEP-C drug, but sales have come off. They made an acquisition. They extract T-cells and re-engineer them to hunt for and kill cancer cells. They get FDA approval in late November. He is concerned that there is a lot of excitement that they will repeat what they did with the HEP-C drug. But they already specialized in HEP-C drugs when they bought that company. They are not in cancer drugs at present. He worries about why the company they acquired sold out at this point.

Show full opinionHide full opinion
Gilead Sciences Inc. (GILD-Q)
September 11, 2017

They made a lot of money on their HEP-C drug, but sales have come off. They made an acquisition. They extract T-cells and re-engineer them to hunt for and kill cancer cells. They get FDA approval in late November. He is concerned that there is a lot of excitement that they will repeat what they did with the HEP-C drug. But they already specialized in HEP-C drugs when they bought that company. They are not in cancer drugs at present. He worries about why the company they acquired sold out at this point.

COMMENT
COMMENT
September 5, 2017

Just made an acquisition of Kite Pharma at a large premium. They have some wonderful oncology drugs. You have to give them the benefit of the doubt because they have a very good track record in terms of acquisitions. Thinks they will be able to use the Kite acquisition to supplement their portfolios. Also, they still have a lot of cash on the balance sheet so they have a lot more options. They can do another acquisition or can buy back stocks. He likes this for the long haul.

Show full opinionHide full opinion

Just made an acquisition of Kite Pharma at a large premium. They have some wonderful oncology drugs. You have to give them the benefit of the doubt because they have a very good track record in terms of acquisitions. Thinks they will be able to use the Kite acquisition to supplement their portfolios. Also, they still have a lot of cash on the balance sheet so they have a lot more options. They can do another acquisition or can buy back stocks. He likes this for the long haul.

BUY WEAKNESS
BUY WEAKNESS
August 21, 2017

It has broken out of the 200 day moving average recently. As long as during any pull back that it holds the 200 and 70 day moving averages, we could expect to see some improvement. We could bounce up to about $80 before we struggle again. If it does not hold the $70 then get out.

Show full opinionHide full opinion

It has broken out of the 200 day moving average recently. As long as during any pull back that it holds the 200 and 70 day moving averages, we could expect to see some improvement. We could bounce up to about $80 before we struggle again. If it does not hold the $70 then get out.

WATCH
WATCH
August 18, 2017

The seasonal strength is June 10 to October 24th. The average is 15% over that period. We did have a nice break of declining trend line resistance. We do have a declining trend line and we are not out of the woods yet. He would hope it could find some support. If it holds $70 you want to be buying it.

Show full opinionHide full opinion

The seasonal strength is June 10 to October 24th. The average is 15% over that period. We did have a nice break of declining trend line resistance. We do have a declining trend line and we are not out of the woods yet. He would hope it could find some support. If it holds $70 you want to be buying it.

COMMENT
COMMENT
August 17, 2017

The potential for this company is for them to use their cash in a positive way. They have about $30 billion of cash on the balance sheet, which represents about 35% of their total market cap. This cash has been acquired because of their hepatitis C portfolio. The drug cures, but costs about $100,000 in the US. However, it is covered by most medical plans. Their opportunity is to make some good acquisitions with their cash hoard.

Show full opinionHide full opinion

The potential for this company is for them to use their cash in a positive way. They have about $30 billion of cash on the balance sheet, which represents about 35% of their total market cap. This cash has been acquired because of their hepatitis C portfolio. The drug cures, but costs about $100,000 in the US. However, it is covered by most medical plans. Their opportunity is to make some good acquisitions with their cash hoard.

PAST TOP PICK
PAST TOP PICK
August 4, 2017

(A Top Pick June 23/16. Down 9.98%.) He still loves this one and has bought more at around $64. The FDA has just approved their drug for hepatitis C. His model price is $119.20, a 60% upside.

Show full opinionHide full opinion

(A Top Pick June 23/16. Down 9.98%.) He still loves this one and has bought more at around $64. The FDA has just approved their drug for hepatitis C. His model price is $119.20, a 60% upside.

TOP PICK
TOP PICK
August 3, 2017

The whole sector has struggled and is cheap. The concern is patent expiry. They have large cash positions and the question is what they are going to do about it. He thinks the stock is mispriced. (Analysts’ target: $81.00).

Show full opinionHide full opinion

The whole sector has struggled and is cheap. The concern is patent expiry. They have large cash positions and the question is what they are going to do about it. He thinks the stock is mispriced. (Analysts’ target: $81.00).

COMMENT
COMMENT
August 3, 2017

This has struggled. It is cheap, trading at about 9X earnings. There has been a resurgence of late, which is positive. The hep C franchise is just not showing tremendous growth, and there are not a lot of things in the pipeline. They have a fair bit of cash. He would prefer Celgene (CELG-Q) on a pullback or Vertex (VRTX-Q), which has had some innovative drugs on multiple sclerosis.

Show full opinionHide full opinion

This has struggled. It is cheap, trading at about 9X earnings. There has been a resurgence of late, which is positive. The hep C franchise is just not showing tremendous growth, and there are not a lot of things in the pipeline. They have a fair bit of cash. He would prefer Celgene (CELG-Q) on a pullback or Vertex (VRTX-Q), which has had some innovative drugs on multiple sclerosis.

PAST TOP PICK
PAST TOP PICK
August 1, 2017

(A Top Pick Sept 6/16. Down 0.4%.) This was in a downtrend, but has finally broken into an uptrend. A cheap, cheap stock, trading at a single digit PE. The #1 provider of HIV drugs globally, and the #1 provider of hepatitis drugs. About 2-3 years ago, they introduced a revolutionary Hepatitis C drug which cured, so the inflow of patients dropped off. Pays about a 3% dividend. Cheap, cheap stock.

Show full opinionHide full opinion

(A Top Pick Sept 6/16. Down 0.4%.) This was in a downtrend, but has finally broken into an uptrend. A cheap, cheap stock, trading at a single digit PE. The #1 provider of HIV drugs globally, and the #1 provider of hepatitis drugs. About 2-3 years ago, they introduced a revolutionary Hepatitis C drug which cured, so the inflow of patients dropped off. Pays about a 3% dividend. Cheap, cheap stock.

COMMENT
COMMENT
July 21, 2017

This had an enormous set back from its peak, and has got to a level that is quite attractive. Has loads and loads of upside potential. Feels the downside risk is now behind it and he likes it here. It could go a fair distance.

Show full opinionHide full opinion

This had an enormous set back from its peak, and has got to a level that is quite attractive. Has loads and loads of upside potential. Feels the downside risk is now behind it and he likes it here. It could go a fair distance.

PAST TOP PICK
PAST TOP PICK
July 11, 2017

(A Top Pick April 14/16. Down 27.5%.) Most of the stocks he picks, when they get cheaper, he likes to buy more. Not only did he buy more in his fund, but he also bought more personally. It is currently at $68.96, and his model price is $114.31, a 65% increase.

Show full opinionHide full opinion

(A Top Pick April 14/16. Down 27.5%.) Most of the stocks he picks, when they get cheaper, he likes to buy more. Not only did he buy more in his fund, but he also bought more personally. It is currently at $68.96, and his model price is $114.31, a 65% increase.

Showing 46 to 60 of 238 entries